# TB-500 Research: Mechanism, Tissue Repair, and the Human-Data Gap > TB-500 research summarized and cited: actin-sequestration mechanism, wound and cardiac findings, the stroke dose-response, the null mdx result, and TB-500 and BPC-157 — sorted by evidence tier. Mechanism first, then the tissue-repair, cardiac, stroke, and comparison findings — each tagged by species and evidence tier, most run on full-length thymosin beta-4. ## TB-500 mechanism of action The LKKTETQ motif binds monomeric (G-) actin 1:1, capping both ends of the monomer to hold a buffered pool of unpolymerized actin [3]. X-ray crystallography of a gelsolin-domain-1–thymosin-beta-4 hybrid bound to actin, resolved to 2 Å, established this dual-end-capping sequestration and identified it as the basis for the broader WH2 protein family [3]. This is the [actin-sequestration mechanism](/research) at the center of TB-500's biology. From that single biochemical job, a cascade of cell-level effects follows in the full protein: regulation of cell migration and motility across keratinocytes, endothelial cells, myoblasts, and progenitor cells [7]. A 2012 review consolidated the mechanism — actin binding, cell mobilization, reduced myofibroblast number and scarring, suppression of NF-κB/IL-8 inflammatory signaling, and promotion of angiogenesis — as the rationale for clinical development in dermal wounds, corneal injury, and heart and CNS repair [7]. A 2024 study attributed part of these effects to specialized pro-resolving pathways [8]. Whether the isolated seven-mer drives the same cascade at peptide-research doses is not established in controlled human trials [5]. ## TB-500 benefits reported in preclinical research The benefits attributed to TB-500 are tissue-repair outcomes measured almost entirely in animals, and overwhelmingly with full-length thymosin beta-4. The wound result is the cleanest: in a rat full-thickness model, topical or intraperitoneal thymosin beta-4 raised re-epithelialization by 42% at four days and up to 61% at seven days versus saline, increased wound contraction by at least 11% by day seven, and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold in vitro [2]. The cardiac finding is the headline mechanistic result: in mice, thymosin beta-4 formed a complex with PINCH and integrin-linked kinase, activated the survival kinase Akt, enhanced early myocyte survival after coronary artery ligation, and improved cardiac function [4]. The hair-follicle benefit — nanomolar thymosin beta-4 activating bulge stem cells — has its own page, the [TB-500 hair follicle research](/hair-follicle-research) [9]. These are genuine, reproducible animal results. None is a demonstrated human benefit of the TB-500 fragment [5]. ## TB-500 and BPC-157 in the research literature TB-500 and BPC-157 are two distinct, unapproved research peptides studied for tissue repair, with different sequences and different mechanisms. TB-500 is the actin-binding fragment of thymosin beta-4; BPC-157 is a separate pentadecapeptide. They are frequently discussed together because both attract athletic-recovery interest, but the published literature does not establish a co-administration benefit. A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance listed both TB-500 and BPC-157 among unapproved peptides showing animal-model promise but scarce human safety data and no regulatory approval [10]. That review is the most direct current source pairing the two: it groups them by regulatory standing, not by any combined-efficacy evidence. The comparison on this board is therefore a status comparison — same tier (unapproved, animal-dominant, no human efficacy trial of the fragment) — and explicitly not a stacking recommendation [10]. ## Heart, stroke, and the findings that temper the story The animal record is not uniformly positive, and the negatives matter. In a rat embolic-stroke dose-response study, intraperitoneal thymosin beta-4 (2, 12, and 18 mg/kg starting 24 hours post-stroke, then every three days for four more doses) improved neurological function at 2 and 12 mg/kg — significant from day 14 through day 56 — but 18 mg/kg gave no significant benefit, and the authors modeled an optimal dose near 3.75 mg/kg [11]. Higher was not better. A companion report confirmed improved functional neurological outcome at the effective doses [12]. Two results push the other way. In dystrophin-deficient mdx mice, chronic thymosin beta-4 increased the number of regenerating muscle fibers but did not improve muscle strength, cardiac function, or fibrosis. And a porcine study found systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury. The 2024 pro-resolving-pathways work adds mechanism on the positive side [8], but the honest summary is mixed: large reproducible wound and structural effects, a non-monotonic stroke curve, and at least two clear null or negative outcomes [11]. See [TB-500 side effects](/faq) for the safety reading. --- The TB-500 record sorted onto one flat status board — each study dropped into its evidence row, the Ac-LKKTETQ fragment kept apart from its parent protein thymosin beta-4, and the empty human-trial row left in plain sight; no clinic stands behind the board and nothing here is dispensed or sold.